Clinical Trial

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2) were included in this study. 20 cases were included in each population, and a total of 40 subjects were planned to be included.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-22.
Trial Details
NCT Number NCT07320586
Lead Sponsor Shandong Tumor Hospital
Conditions Gastric Cancer, Second-line Therapy
Enrollment 40 participants
Start Date 2021-03-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-13